ARID1A mutation: A new target for efficient cancer immunotherapy
-
-
REFERENCES
[1] Ribas, A., and Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science 359: 1350−1355. DOI: 10.1126/science.aar4060. [2] Maxwell, M.B., Hom-Tedla, M.S., Yi, J., et al. (2024). ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell 187: 3390−3408.e3319. DOI: 10.1016/j.cell.2024.04.025. [3] Hu, G.Y., Tu, W., Yang, L., et al. (2020). ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Lett. 473: 148−155. DOI: 10.1016/j.canlet.2020.01.001. [4] Zhou, W., Liu, H., Yuan, Z., et al. (2023). Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell 41: 740−756.e710. DOI: 10.1016/j.ccell.2023.03.002. [5] Park, Y., Chui, M.H., Suryo Rahmanto, Y., et al. (2019). Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin. Cancer Res. 25: 5584−5594. DOI: 10.1158/1078-0432.Ccr-18-4222. -
ABOUT THIS ARTICLE
Cite this article:
Chen H., Guo G., Wu M., et al., (2024). ARID1A mutation: A new target for efficient cancer immunotherapy. The Innovation Medicine 2(4): 100101. https://doi.org/10.59717/j.xinn-med.2024.100101
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Chen H., Guo G., Wu M., et al., (2024). ARID1A mutation: A new target for efficient cancer immunotherapy. The Innovation Medicine 2(4): 100101. https://doi.org/10.59717/j.xinn-med.2024.100101
Format
Content
DownLoad:
-
Figure 1.
Molecular mechanisms and application scenarios of ARID1A-mutant tumor
